Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring
<p>Abstract</p> <p>Background</p> <p>In Fabry disease (α-galactosidase A deficiency) accumulation of Globotriaosylceramide (Gb3) leads to progressive organ failure and premature death. The introduction of enzyme replacement therapy (ERT) was the beginning of a new era i...
Main Author: | Hoffmann Björn |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-10-01
|
Series: | Orphanet Journal of Rare Diseases |
Online Access: | http://www.ojrd.com/content/4/1/21 |
Similar Items
-
The Challenge of Diagnosis and Indication for Treatment in Fabry Disease
by: Marco A. Curiati MD, et al.
Published: (2017-01-01) -
Recommendation for diagnosis and treatment of fabry’s disease in Slovenia
by: Bojan Vujkovac, et al.
Published: (2006-12-01) -
Pathologic substrate of gastropathy in Anderson-Fabry disease
by: Alessandro Di Toro, et al.
Published: (2020-06-01) -
Recent Advances in the Diagnosis and Treatment of Chronic Liver Diseases
Published: (2022) -
Fabry disease, a complex pathology not easy to diagnose
by: Paolo Colomba, et al.
Published: (2015-12-01)